Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-12-31

Summary

This is a Phase II, prospective, randomized, open label, controlled, multi-center study, aim to evaluate the activity of Tislelizumab and Anlotinib and chemotherapy compared with Tislelizumab and chemotherapy before surgery, followed by Tislelizumab alone as adjuvant therapy. The primary objective of this study is to evaluate and compare pathological complete response rate(pCR).

• Phase: PHASE2

Details

• Lead Sponsor: Tang-Du Hospital
• Treatments: Albumin-Bound Paclitaxel; Angiogenesis Inhibitors; anlotinib; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; tislelizumab